{"paper_id":"704f30ca-e795-4fe8-b4eb-52692eeefb14","body_text":"Increased local prolactin synthesis in the myometrium and endometrium as a probable cause of adenomyosis\n- Authors: Malysheva O.V.1, Yarmolinskaya M.I.1, Shalina M.A.1, Glotov A.S.1\n-\nAffiliations:\n- The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott\n- Issue: Vol 75, No 4 (2026)\n- Pages: 36-44\n- Section: Original study articles\n- Submitted: 24.06.2026\n- Accepted: 06.07.2026\n- Published: 24.08.2026\n- URL: https://journals.eco-vector.com/jowd/article/view/713728\n- DOI: https://doi.org/10.17816/JOWD713728\n- EDN: https://elibrary.ru/SWMOTA\n- ID: 713728\nCite item\nAbstract\nBACKGROUND: Adenomyosis is a gynecological condition characterized by the abnormal presence of endometrial glands and stroma within the deeper layers of the myometrium. The role of prolactin in the development of adenomyosis was established earlier in experiments that showed that experimentally induced hyperprolactinemia, both local and systemic, can cause adenomyosis in animal models. Prolactin is also known to be synthesized locally in the female reproductive system, namely, in the endometrium and myometrium.\nAIM: The aim of this study was to evaluate prolactin gene expression levels in the tissues of the female reproductive system (endometrium, myometrium) in patients with adenomyosis compared with the control group and women with other gynecological diseases (endometriosis, uterine fibroids).\nMETHODS: The real-time reverse transcription polymerase chain reaction method was used to evaluate prolactin gene expression in the endometrium of 104 patients with various hyperproliferative gynecological diseases, such as adenomyosis, uterine fibroids, and endometriosis, as well as in patients of the comparison group. Prolactin gene expression in the myometrium of 17 patients (8 women in the comparison group and 9 women with adenomyosis) was also analyzed.\nRESULTS: We found a significant increase in prolactin mRNA in the endometrium and myometrium of patients with adenomyosis. Some patients with uterine fibroids or endometriosis and women in the comparison group may experience sharp increases in prolactin mRNA, however, these changes are not systematic.\nCONCLUSION: The data obtained indicate the important role of local hyperprolactinemia in the pathogenesis of adenomyosis.\nKeywords\nFull Text\nAbout the authors\nOlga V. Malysheva\nThe Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott\nAuthor for correspondence.\nEmail: omal99@mail.ru\nORCID iD: 0000-0002-8626-5071\nSPIN-code: 1740-2691\nCand. Sci. (Biology)\nRussian Federation, Saint PetersburgMaria I. Yarmolinskaya\nThe Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott\nEmail: m.yarmolinskaya@gmail.com\nORCID iD: 0000-0002-6551-4147\nSPIN-code: 3686-3605\nCand. Sci. (Biology)\nRussian Federation, Saint PetersburgMaria A. Shalina\nThe Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott\nEmail: amarus@inbox.ru\nORCID iD: 0000-0002-5921-3217\nSPIN-code: 6673-2660\nMD, Cand. Sci. (Medicine)\nRussian Federation, Saint PetersburgAndrey S. Glotov\nThe Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott\nEmail: anglotov@mail.ru\nORCID iD: 0000-0002-7465-4504\nSPIN-code: 1406-0090\nDr. Sci. (Biology)\nRussian Federation, Saint PetersburgReferences\n- Hashimoto A, Iriyama T, Sayama S, et al. Adenomyosis and adverse perinatal outcomes: increased risk of second trimester miscarriage, preeclampsia, and placental malposition. J Matern Fetal Neonatal Med. 2018;31(3):364–369. doi: 10.1080/14767058.2017.1285895\n- Habiba M, Benagiano G, Guo SW. An Appraisal of the Tissue Injury and Repair (TIAR) theory on the pathogenesis of endometriosis and adenomyosis. Biomolecules. 2023;13(6):975. doi: 10.3390/biom13060975 EDN: CUMQJT\n- Greaves P, White IN. Experimental adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):503–10. doi: 10.1016/j.bpobgyn.2006.01.003\n- Mori T, Singtripop T, Kawashima S. Animal model of uterine adenomyosis: is prolactin a potent inducer of adenomyosis in mice? Am J Obstet Gynecol. 1991;165(1):232–4. doi: 10.1016/0002-9378(91)90258-s\n- Wang R, Xu S, Cui Q, et al. Single-cell RNA sequencing identifies the prolactin receptor as a therapeutic target in adenomyosis. Signal Transduct Target Ther. 2025;10(1):258. doi: 10.1038/s41392-025-02339-z EDN: NWVWLW\n- Dzeranova LK, Tabeeva LI. Successes, problems and prospects of prolactin research. Russian Chemical Journal. 2005;(1):84–93. (In Russ.)\n- Auriemma RS, Del Vecchio G, Scairati R, et al. The interplay between prolactin and reproductive system: focus on uterine pathophysiology. Front Endocrinol (Lausanne). 2020;11:594370. doi: 10.3389/fendo.2020.594370 EDN: UOGEKA\n- Maslar IA, Riddick DH. Prolactin production by human endometrium during the normal menstrual cycle. Am J Obstet Gynecol. 1979;135(6):751–754. doi: 10.1016/0002-9378(79)90386-7\n- Walters CA, Daly DC, Chapitis J, et al. Human myometrium: a new potential source of prolactin. Am J Obstet Gynecol. 1983;147(6):639–644. doi: 10.1016/0002-9378(83)90441-6\n- Patent RUS № RU2764106/ 13.01.2022. Nagorneva SV, Shalina MA, Yarmolinskaya MI, et al. Method of diagnosis of adenomyosis. Available from: https://patenton.ru/patent/RU2764106C1?ysclid=moctdb49zd267073198 (In Russ.) EDN: BCYRSL\n- Endometriosis. Clinical guidelines. Moscow: Russian Society of Obstetricians and Gynecologists; 2024:62. (In Russ.)\n- Huseby RA, Soares MJ, Talamantes F. Ectopic pituitary grafts in mice: hormone levels, effects on fertility, and the development of adenomyosis uteri, prolactinomas, and mammary carcinomas. Endocrinology. 1985;116(4):1440–8. doi: 10.1210/endo-116-4-1440\n- Mori T, Nagasawa H. Mechanisms of development of prolactin-induced adenomyosis in mice. Acta Anat (Basel). 1983;116(1):46–54. doi: 10.1159/000145724\n- Khattab S, Yu CH, Shah S. Prolactinoma and adenomyosis — more than meets the eye: a case report. AACE Clin Case Rep. 2023;10(1):20–23. doi: 10.1016/j.aace.2023.11.002\n- Łupicka M, Socha BM, Szczepańska AA, et al. Prolactin role in the bovine uterus during adenomyosis. Domest Anim Endocrinol. 2017;58:1–13. doi: 10.1016/j.domaniend.2016.07.003\n- Frantsiyants EM, Bandovkina VA, Moiseenko TI, Chernikova NV. The level of sex hormones in the tissues and myoma adenomyosis at the independent and combined development. Russian journal of oncology. 2013;(6):24–27. EDN: RTIYHT\n- Yang J, Li X, Peng Y, et al. Pathogenesis of adenomyosis: an integrated review of cellular origins, molecular mechanisms, and intersecting diseases. J Cell Mol Med. 2026;30(7):e71129. doi: 10.1111/jcmm.71129 EDN: RGNATA\n- Cope AG, Ainsworth AJ, Stewart EA. Current and future medical therapies for adenomyosis. Semin Reprod Med. 2020;38(2-03):151–156. doi: 10.1055/s-0040-1719016 EDN: WLTEUO\n- Andersson JK, Khan Z, Weaver AL, et al. Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: a pilot study. Acta Obstet Gynecol Scand. 2019;98(10):1341–1350. doi: 10.1111/aogs.13632\n- Tang Y, Ponandai-Srinivasan S, Frisendahl C, et al. Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis. Front Endocrinol (Lausanne). 2023;14:1026168. doi: 10.3389/fendo.2023.1026168 EDN: XFBWJR\n- Hakimi P, Eghbali E, Alborzi M, et al. The impact of vaginal bromocriptine on reducing pain and menstrual bleeding in women with adenomyosis: a randomized controlled trial. Sci Rep. 2026;16:24086. doi: 10.1038/s41598-026-53524-1\n- Featherstone K, White MRH, Davis JRE. The prolactin gene: a paradigm of tissue-specific gene regulation with complex temporal transcription dynamics. Journal of Neuroendocrinology. 2012;24:977–990. doi: 10.1111/j.1365-2826.2012.02310.x\n- Otto C, Ulbrich HF, Freiberg C. The effects of prolactin receptor blockade in a murine endometriosis interna model. Pharmacol Res Perspect. 2022;10(1):e00916. doi: 10.1002/prp2.916 EDN: YOFOLN\n- Nave R, Jodl S, Hoffmann A, et al. Monoclonal antibody against prolactin receptor: a randomized placebo-controlled study evaluating safety, tolerability, and pharmacokinetics of repeated subcutaneous administrations in postmenopausal women. Reprod Sci. 2019;26(4):523–531. doi: 10.1177/1933719118776806.2026 EDN: DZCNGZ\n- Yamashita M, Matsuda M, Mori T. In situ detection of prolactin receptor mRNA and apoptotic cell death in mouse uterine tissues with adenomyosis. In Vivo. 1999;13(1):57–60.","source_license":"CC0","license_restricted":false}